VOTRIENT (pazopanib)
SELF ADMINISTRATION - ORAL
Indications for Prior Authorization:
- Treatment of advanced renal cell carcinoma
- Advanced soft tissue sarcoma in patient who have received previous chemotherapy
The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P & T Committee:
- All non-FDA approved uses not listed in the approved indications
Dosing:
- 800 mg once daily without food
- 200 mg once daily for patient with moderate hepatic impairment
- Not recommend for patient with severe hepatic impairment
Warning:
- Severe and fatal hepatotoxicity was observed in clinical trial
Approval:
- Initial approval 6 weeks
- Renewal: 6 months
Last review date: December 2, 2013